Alemtuzumab, an anti-CD52 monoclonal antibody,1 is a disease-modifying therapy (DMT) used to treat active relapsing-remitting multiple sclerosis (RRMS) in two cycles 1 year apart. This evidence concerns the gene CD52 and relapsing-remitting multiple sclerosis.